Home › Pancreatic Cancer › NCT05914987

Determining Individualized Cancer Therapy in Pancreatic Cancer

Profile-Related Evidence Determining Individualized Cancer Therapy in Pancreatic Cancer (PREDICT-PANC)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age ≥18 years.
* Pathologically confirmed pancreatic cancer.
* Ability to understand a written informed consent document and the willingness to sign it

Exclusion Criteria:

* Age \<18 years.
* Primary cancer diagnosis other than pancreatic cancer.

About the study

This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.

What is being tested

• Targeted Therapy (other)

Sponsor: Medical College of Wisconsin · Participants: 1,000 · Started: Dec 4, 2023

Contact the study team

• Cancer Center Clinical Trials Office · Phone: 1-414-805-8900

Official record on ClinicalTrials.gov — NCT05914987

Locations in the U.S.

Conditions

• Pancreatic Cancer
• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.